GlassScriptPhysician profile
George P Liakeas
NPI 1417049727
$15,845.34
in general payments reported to CMS, 2019-2025
53 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $1,658 · 2021: $1,249 · 2022: $1,537 · 2023: $853 · 2024: $210 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,374.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $8,887.49 | 2019-2023 | |
| Abbvie INC. | $1,106.01 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $560.44 | 2019-2023 | Xifaxan, Trulance |
| Allergan, INC. | $506.49 | 2019-2020 | |
| Novo Nordisk INC | $397.73 | 2019-2023 | Wegovy |
| Pfizer INC. | $306.63 | 2019-2023 | |
| Glaxosmithkline, LLC. | $278.41 | 2019-2024 | Arexvy, Shingrix |
| Lilly USA, LLC | $275.44 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $267.83 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $247.31 | 2019-2023 | Trintellix |
| Galderma Laboratories, L.P. | $239.07 | 2021-2025 | |
| Bausch Health US, LLC | $227.61 | 2019-2022 | |
| Amgen INC. | $221.12 | 2019-2022 | |
| Amarin Pharma, INC. | $204.29 | 2019-2022 | |
| Merz North America, INC. | $195.07 | 2019-2020 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Liakeas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.